Cooley and Covington & Burling have scored roles in AstraZeneca's $1bn acquisition of Belgian cancer treatment company ...
Alexion Pharmaceuticals’ ravulizumab for the prevention of delayed graft function after renal transplantation was granted FDA orphan ...
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
The FTSE 100 company, which has a market capitalisation of £185.9 billion, confirmed the deal in an announcement to the ...
Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback